Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

DETERMINE-reduced - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Reduced Ejection Fraction

ClinicalTrials.gov ID: NCT03877237

Public ClinicalTrials.gov record NCT03877237. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 3:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

International, Multicentre, Parallel-group, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the Effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients With Reduced Ejection Fraction

Study identification

NCT ID
NCT03877237
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
AstraZeneca
Industry
Enrollment
313 participants

Conditions and interventions

Interventions

  • Dapagliflozin Drug
  • Placebo Other

Drug · Other

Eligibility (public fields only)

Age range
18 Years to 150 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 8, 2019
Primary completion
Mar 6, 2020
Completion
Mar 6, 2020
Last update posted
May 4, 2021

2019 – 2020

United States locations

U.S. sites
23
U.S. states
15
U.S. cities
22
Facility City State ZIP Site status
Research Site Alexander City Alabama 35010
Research Site Fairhope Alabama 36532
Research Site Fort Payne Alabama 35967
Research Site Mobile Alabama 36608
Research Site Beverly Hills California 90211
Research Site Torrance California 90502
Research Site Stamford Connecticut 06905
Research Site Miami Florida 33133
Research Site Miami Florida 33173
Research Site Tucker Georgia 30084
Research Site Munster Indiana 46321
Research Site Petoskey Michigan 49770
Research Site Kansas City Missouri 64111
Research Site New Brunswick New Jersey 08901
Research Site Buffalo New York 14215
Research Site New York New York 10001
Research Site Rosedale New York 11422
Research Site Burlington North Carolina 27215
Research Site Abington Pennsylvania 19001
Research Site Pittsburgh Pennsylvania 15212
Research Site Tullahoma Tennessee 37388
Research Site Falls Church Virginia 22042
Research Site Seattle Washington 98101

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 53 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03877237, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 4, 2021 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03877237 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →